InterventionsHumans28,639 participantsCohort study

Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Figure 1 from Diabetes Therapy
Open the figure at full size
Figure 1Tan et al.

Diabetes Therapy

The paper

Novo Nordisk (United States) · Yale University

Diabetes Therapy · 17 Sep 2026

doi.org/10.1007/s13300-026-01919-8PubMed 42753116

More on GLP-1 and incretin signalling